UBS Group
TAK icon

UBS Group’s Takeda Pharmaceutical TAK Stock Holding History

UBS Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Sell
911,319
-1,828,910
-67% -$30.3M ﹤0.01% 3017
2026
Q1 		$50.7M Sell
2,740,229
-1,383,294
-34% -$24.3M 0.01% 1621
2025
Q4 		$64.3M Sell
4,123,523
-1,770,446
-30% -$25.3M 0.01% 1376
2025
Q3 		$86.3M Buy
5,893,969
+1,869,323
+46% +$27.8M 0.01% 1138
2025
Q2 		$62.2M Buy
4,024,646
+2,270,084
+129% +$33.5M 0.01% 1311
2025
Q1 		$26.1M Buy
1,754,562
+92,930
+6% +$1.3M ﹤0.01% 2099
2024
Q4 		$22M Buy
1,661,632
+1,588,617
+2,176% +$21.8M ﹤0.01% 2223
2024
Q3 		$1.04M Sell
73,015
-41,456
-36% -$588K ﹤0.01% 4622
2024
Q2 		$1.48M Buy
114,471
+18,244
+19% +$242K ﹤0.01% 4054
2024
Q1 		$1.34M Buy
96,227
+33,138
+53% +$482K ﹤0.01% 4349
2023
Q4 		$900K Buy
63,089
+11,704
+23% +$166K ﹤0.01% 4596
2023
Q3 		$795K Sell
51,385
-158,520
-76% -$2.45M ﹤0.01% 4288
2023
Q2 		$3.3M Buy
209,905
+127,439
+155% +$2.09M ﹤0.01% 3006
2023
Q1 		$1.36M Sell
82,466
-33,686
-29% -$537K ﹤0.01% 3823
2022
Q4 		$1.81M Sell
116,152
-7,852
-6% -$110K ﹤0.01% 3479
2022
Q3 		$1.61M Buy
124,004
+9,703
+8% +$135K ﹤0.01% 3352
2022
Q2 		$1.6M Buy
114,301
+7,901
+7% +$113K ﹤0.01% 3329
2022
Q1 		$1.52M Sell
106,400
-204,280
-66% -$3M ﹤0.01% 3694
2021
Q4 		$4.23M Buy
310,680
+39,371
+15% +$552K ﹤0.01% 3001
2021
Q3 		$4.44M Buy
271,309
+17,192
+7% +$289K ﹤0.01% 2793
2021
Q2 		$4.28M Sell
254,117
-13,065
-5% -$222K ﹤0.01% 2857
2021
Q1 		$4.88M Buy
267,182
+166,659
+166% +$3M ﹤0.01% 2622
2020
Q4 		$1.83M Buy
100,523
+17,079
+20% +$300K ﹤0.01% 3479
2020
Q3 		$1.49M Sell
83,444
-3,502
-4% -$63.8K ﹤0.01% 3334
2020
Q2 		$1.56M Buy
86,946
+15,006
+21% +$269K ﹤0.01% 3117
2020
Q1 		$1.09M Buy
71,940
+676
+0.9% +$12.3K ﹤0.01% 3275
2019
Q4 		$1.41M Sell
71,264
-3,238
-4% -$61.9K ﹤0.01% 3895
2019
Q3 		$1.28M Sell
74,502
-13,848
-16% -$239K ﹤0.01% 3739
2019
Q2 		$1.56M Sell
88,350
-136,367
-61% -$2.48M ﹤0.01% 3372
2019
Q1 		$4.58M Sell
224,717
-9,923,879
-98% -$200M ﹤0.01% 2281
2018
Q4 		$171M Buy
+10,148,596
New +$171M 0.08% 241

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group's TAK Position: Q2 2026 in Review

UBS Group reduced its Takeda Pharmaceutical (TAK) stake by 67% in Q2 2026, selling an estimated $30.3M and leaving 911,319 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3017.

UBS Group first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $171M in Q4 2018. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • UBS Group held 911,319 shares of Takeda Pharmaceutical worth $14.6M as of Q2 2026.
  • UBS Group sold 1,828,910 Takeda Pharmaceutical shares in Q2 2026, an estimated $30.3M.
  • Takeda Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3017 holding.
  • UBS Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • UBS Group's Takeda Pharmaceutical position peaked at $171M in Q4 2018.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.